For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS), the leading developer of therapeutics targeting lysyl oxidase enzymes to treat fibrosis and cancer, announced it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for a planned phase 1/2 study of PXS-5505 for the treatment of myelofibrosis. The protocol incorporates a one-month dose escalation phase followed by 6 months’ treatment in an open label study of patients who are not on a JAK inhibitor. The study is planned to commence in Q4 2020 and expected to conclude in 2022.Read full media release - pdf
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced that the U.S. Food & Drug Administration (FDA) has granted orphan-drug designation for its oral pan LOX inhibitor PXS-5505 for the treatment of myelofibrosis.Read full media release - pdf